EP Patent

EP4134083A1 — Pharmaceutical compositions of bortezomib

Assigned to Extrovis AG · Expires 2023-02-15 · 3y expired

What this patent protects

The present invention relates to a sterile, ready-to-use, aqueous composition of bortezomib that is stable over its shelf life.

USPTO Abstract

The present invention relates to a sterile, ready-to-use, aqueous composition of bortezomib that is stable over its shelf life.

Drugs covered by this patent

Cytoxan (Lyophilized) (cyclophosphamide) · Baxter

Patent Metadata

Patent number: EP4134083A1
Jurisdiction: EP
Classification: —
Expires: 2023-02-15
Drug substance claim: No
Drug product claim: No
Assignee: Extrovis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.